2025 is shaping up to be a defining year for Biosergen, the antifungal drug developer with a mission to combat life-threatening fungal infections. During the second quarter, the biotech company has advanced its clinical program for BSG005, made key leadership appointments, and laid out the next steps toward pivotal studies. We contacted CEO Tine Olesen to learn more about what lies ahead.
Read the full interview at biostock.se:
https://biostock.se/en/2025/08/biosergens-ceo-on-the-preparations-for-the-next-clinical-phase/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/